21.69 USD
+1.42 (+7.01%)
21.7 USD
+0.01 (+0.05%)
ChartMill assigns a Buy % Consensus number of 79% to KROS. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 23.72. This target is 9.34% above the current price.
KROS was analyzed by 17 analysts. The buy percentage consensus is at 79. So analysts seem to be have mildly positive about KROS.
In the previous month the buy percentage consensus was at a similar level.
KROS was analyzed by 17 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-11-28 | B of A Securities | Maintains | Neutral -> Neutral |
| 2025-11-12 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2025-11-11 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-11-06 | Wedbush | Maintains | Neutral -> Neutral |
| 2025-08-08 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-06-10 | B of A Securities | Downgrade | Buy -> Neutral |
| 2025-05-30 | Wedbush | Reiterate | Neutral -> Neutral |
| 2025-05-12 | ScotiaBank | Maintains | Sector Outperform -> Sector Outperform |
| 2025-05-08 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-04-09 | Truist Securities | Maintains | Buy -> Buy |
| 2025-04-01 | Wedbush | Reiterate | Neutral -> Neutral |
| 2025-04-01 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-27 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-02-27 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-01-21 | Cantor Fitzgerald | Downgrade | Overweight -> Neutral |
| 2025-01-17 | Guggenheim | Reiterate | Neutral -> Neutral |
| 2025-01-17 | Wedbush | Downgrade | Outperform -> Neutral |
| 2025-01-17 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-01-16 | ScotiaBank | Maintains | Sector Outperform -> Sector Outperform |
| 2025-01-16 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-12-23 | Truist Securities | Maintains | Buy -> Buy |
| 2024-12-16 | Guggenheim | Downgrade | Buy -> Neutral |
| 2024-12-16 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-12-13 | ScotiaBank | Maintains | Sector Outperform -> Sector Outperform |
| 2024-12-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-12 | TD Cowen | Downgrade | Buy -> Hold |
| 2024-12-12 | William Blair | Downgrade | Outperform -> Market Perform |
| 2024-12-12 | BTIG | Downgrade | Buy -> Neutral |
| 2024-12-11 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2024-12-05 | Guggenheim | Maintains | Buy -> Buy |
KEROS THERAPEUTICS INC / KROS FAQ
What is the price target for KROS stock?
17 analysts have analysed KROS and the average price target is 23.72 USD. This implies a price increase of 9.34% is expected in the next year compared to the current price of 21.69.
How do analysts rate KEROS THERAPEUTICS INC (KROS)?
The consensus rating for KEROS THERAPEUTICS INC (KROS) is 78.8235 / 100 . This indicates that analysts generally have a positive outlook on the stock.